Literature DB >> 32671545

A comparison of IVF outcomes transferring a single ideal blastocyst in women with polycystic ovary syndrome and normal ovulatory controls.

Naama Steiner1,2, Senem Ates3, Talya Shaulov3, Guy Shrem3,4, Alexander Volodarsky-Perel3,4, S Yehuda Dahan5, Samer Tannus3, Weon-Young Son3,4, Michael H Dahan3,4.   

Abstract

PURPOSE: To assess the effects PCOS on live birth rates when transferring a single fresh ideal blastocyst.
METHODS: A retrospective cohort study performed at the university-affiliated reproductive center. Women with PCOS and a control group of normal ovulatory women who underwent their first fresh embryo transfer with single ideal grade blastocyst were included in the study. Demographic, stimulation information and pregnancy outcomes were collected and analysed. The primary outcome was live birth rates, and secondary outcomes included pregnancy and clinical pregnancy rates.
RESULTS: 71 Women with PCOS and 272 normal ovulatory controls underwent their first embryo transfer and met the inclusion and exclusion criteria. PCOS patient were younger (31.0 ± 3.7 vs. 33.1 ± 3.2, p = 0.0001), with higher AFC (40.0 ± 9.3 vs. 13.3 ± 4.6, p = 0.0001), required lower dose of gonadotropins to stimulate (1198 ± 786 vs. 1891 ± 1224, p = 0.0001), and had higher serum testosterone levels (2.3 ± 0.7 vs. 1.1 ± 0.3, p = 0.0001). No significant difference was found between the two groups regarding the number of previous pregnancies, the number of previous full-term pregnancies, the level of basal serum FSH, estradiol level at triggering and the BMI. When compared by Chi squared testing pregnancy rates, clinical pregnancy rates and live birth rates did not differ. However, when controlling (with multivariate stepwise logistic regression) for confounders, live birth rates were lower among the women with PCOS (p = 0.035, CI: 0.18-0.92).
CONCLUSION: After controlling for confounders, when transferring a fresh single ideal blastocyst, live birth rates were lower among the women with PCOS than normal ovulatory controls.

Entities:  

Keywords:  Blastocyst; Hyperandrogenism; IVF; PCOS

Mesh:

Substances:

Year:  2020        PMID: 32671545     DOI: 10.1007/s00404-020-05699-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  34 in total

1.  Predicting pregnancy in women undergoing in-vitro fertilization with basal serum follicle stimulating hormone levels between 10.0 and 11.9 IU/L.

Authors:  Dan Levin; Sunny H Jun; Michael H Dahan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

2.  Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment.

Authors:  Hang Wun Raymond Li; Vivian Chi Yan Lee; Estella Yee Lan Lau; William Shu Biu Yeung; Pak Chung Ho; Ernest Hung Yu Ng
Journal:  J Assist Reprod Genet       Date:  2013-12-14       Impact factor: 3.412

3.  Does ovarian reserve affect outcomes in single ideal blastocyst transfers in women less than 40 years of age?

Authors:  Andrew Zakhari; Senem Ates; Talya Shaulov; Michael H Dahan
Journal:  Arch Gynecol Obstet       Date:  2017-10-29       Impact factor: 2.344

4.  Lack of association between polycystic ovary syndrome and embryonic aneuploidy.

Authors:  Andrea Weghofer; Santiago Munne; Serena Chen; David Barad; Norbert Gleicher
Journal:  Fertil Steril       Date:  2007-04-16       Impact factor: 7.329

5.  A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome.

Authors:  E M E W Heijnen; M J C Eijkemans; E G Hughes; J S E Laven; N S Macklon; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2005-08-25       Impact factor: 15.610

6.  Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study.

Authors:  R Koivunen; A Pouta; S Franks; H Martikainen; U Sovio; A-L Hartikainen; M I McCarthy; A Ruokonen; A Bloigu; M-R Järvelin; L Morin-Papunen
Journal:  Hum Reprod       Date:  2008-06-10       Impact factor: 6.918

Review 7.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

8.  Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.

Authors:  Richard S Legro; Silva A Arslanian; David A Ehrmann; Kathleen M Hoeger; M Hassan Murad; Renato Pasquali; Corrine K Welt
Journal:  J Clin Endocrinol Metab       Date:  2013-10-22       Impact factor: 5.958

9.  Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.

Authors:  Helena J Teede; Marie L Misso; Michael F Costello; Anuja Dokras; Joop Laven; Lisa Moran; Terhi Piltonen; Robert J Norman
Journal:  Hum Reprod       Date:  2018-09-01       Impact factor: 6.918

10.  Assisted reproduction in polycystic ovarian disease: A multicentric trial in India.

Authors:  Pratap Kumar; Natasha Nawani; Narendra Malhotra; Jaideep Malhotra; Madhuri Patil; K Jayakrishnan; Sujata Kar; Padma Rekha Jirge; Nalini Mahajan
Journal:  J Hum Reprod Sci       Date:  2013-01
View more
  3 in total

1.  Quantitative Proteomics Reveals That a Prognostic Signature of the Endometrium of the Polycystic Ovary Syndrome Women Based on Ferroptosis Proteins.

Authors:  Jian Zhang; Nan Ding; Wenhu Xin; Xin Yang; Fang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

2.  Live birth outcomes in infertile patients with class III and class IV obesity following fresh embryo transfer.

Authors:  Phillip A Romanski; Pietro Bortoletto; Brady Magaoay; Alice Chung; Zev Rosenwaks; Steven D Spandorfer
Journal:  J Assist Reprod Genet       Date:  2020-11-16       Impact factor: 3.412

Review 3.  The Complicated Effects of Extracellular Vesicles and Their Cargos on Embryo Implantation.

Authors:  Nan-Xing Jiang; Xue-Lian Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.